Although doxorubicin and dinaciclib had more prompt and profound effects on reducing the expression of MCL-1 than BCL-2 and BCL-XL, we found that prolonged treatment of SCLC cells with these agents also partially reduced BCL-XL (Fig. 6a). This evidence concerns the gene BCL2 and small cell lung carcinoma.